Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab + Magrolimab in AML and MDS
NCT05367401Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2024
- Primary completion
- Oct 2029
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of sabatolimab and magrolimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities and Complete Remission up to 4 years. Planned start Dec 2024; status: withdrawn.
02
Drugs
sabatolimabmagrolimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05367401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367401.